Who
Steven A. Shallcross
CEO and CFO
Company insider
Files Form 4 as: CEO and CFO, Theriva Biologics; Director, Elys Game Technology; Director, Twin Vee PowerCats Co; Chief Financial Officer, Cytomedix; Sr. VP, CFO, Treasurer, Vanda Pharmaceuticals.
In numbers
- Trades disclosed
- 93
- Buys
- 11
- Sells
- 13
- Bought
- $236K
- Sold
- $976K
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 11 Dec 2006
- Last trade
- 5 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jan 2026filed 6 Jan 2026 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —475,000 at $0.00 | filing |
| 5 Jan 2026filed 6 Jan 2026 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —475,000 at $0.00 | filing |
| 29 Apr 2025filed 1 May 2025 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,000 at $0.00 | filing |
| 14 Dec 2023filed 15 Dec 2023 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 7 Jun 2023filed 8 Jun 2023 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $9,66014,000 at $0.69 | filing |
| 6 Jun 2023filed 7 Jun 2023 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $16K26,000 at $0.63 | filing |
| 14 Feb 2023filed 16 Feb 2023 | Elys Game Technologyoption or derivative | SEC FORM 4 Code A | —39,377 at $0.00 | filing |
| 14 Feb 2023filed 16 Feb 2023 | Elys Game Technologyoption or derivative | SEC FORM 4 Code A | —92,254 at $0.00 | filing |
| 14 Feb 2023filed 16 Feb 2023 | Elys Game Technology | SEC FORM 4 Code A | $20K22,472 at $0.89 | filing |
| 10 Feb 2023filed 13 Feb 2023 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $26K25,000 at $1.04 | filing |
| 2 Feb 2023filed 3 Feb 2023 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $24K25,000 at $0.94 | filing |
| 25 Jan 2023filed 26 Jan 2023 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $22K25,000 at $0.87 | filing |
| 20 Jan 2023filed 23 Jan 2023 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $19K25,000 at $0.75 | filing |
| 29 Dec 2022filed 3 Jan 2023 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $44K100,000 at $0.44 | filing |
| 15 Dec 2022filed 16 Dec 2022 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —475,000 at $0.00 | filing |
| 23 Dec 2021filed 27 Dec 2021 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 13 Sep 2021filed 15 Sep 2021 | Elys Game Technologyoption or derivative | SEC FORM 4 Code A | —13,600 at $0.00 | filing |
| 23 Jul 2021filed 26 Jul 2021 | VEEE Twin Vee PowerCats Cooption or derivative · Leisure Products & Vehicles | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 10 May 2021filed 10 May 2021 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $25K50,000 at $0.49 | filing |
| 22 Jan 2021filed 27 Jan 2021 | Elys Game Technology | SEC FORM 4 Code A | $30K5,245 at $5.72 | filing |
News
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramVNDA · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Steven A. Shallcross; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.